As the business of clinical trials evolves into a more complex, cloud-based realm, placing a high premium on an end-to-end monitoring strategy is most crucial. Risk assessment is a very important first step in an organization’s overall monitoring efforts and a major driver for sponsors’ monitoring efforts - as detailed in the amended ICH E6 GCP (good clinical practice) guidelines on risk assessment - yet many sponsors still view it as a routine trial exercise.

Our October 25 webinar, “The future of monitoring compliance: implications & technology”, will focus on understanding ICH E6 as the main driver of an end-to-end risk management approach, and how we can leverage it to more effectively implement a superior risk-based monitoring strategy that ultimately leads to increased compliance and better patient outcomes.

Featured Speakers:

Lori Convy
Principal, Platform Adoption, RBM
Medidata

Lori brings more than 20 years of industry experience in various trial monitoring capacities. At Medidata, Lori is working to shape and help execute Medidata’s Risk-Based Monitoring and Central Statistical Analysis market strategy. Prior to Medidata, Lori represented Sanofi on the TransCelerate RBM work stream as a founding member driving RBM implementation facilitation.

Daniel O’Connell
Principal, Platform Adoption, RBM
Medidata

Dan brings 18 years of industry experience from across both Pharma and CROs, most recently serving as the Associate Director of Clinical Innovation at INC Research where he was responsible for providing customers with “fit for purpose” RBM methodology and technology implementation. At Medidata, Dan is working to shape and help execute Medidata’s Risk-Based Monitoring and Central Statistical Analysis market strategy.

Date: Wednesday, October 25, 2017
Time: 11 am ET / 8 am PT
Duration: 1 Hour

Register now for this webinar